Drug Trial Radar · NCT06463587
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
264
Planned (sponsor's estimate)
Start
Jun 25, 2024
Primary completion
Aug 23, 2028
Study completion Nov 12, 2030
Sponsor
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- Collaborators
- EMD Serono Research & Development Institute, Inc.
- First posted
- Jun 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of oral cladribine in gMG. An additional component is included to characterize the Pharmacokinetics (PK) of the new cladribine formulation in gMG participants. This study is divided into 3 periods: the double-blind placebo control (DBPC) pivotal period, and 2 extensions, the blinded extension (BE) and the retreatment (RT) period. Furthermore, in trial interviews will be conducted as a sub-study to MyClad with a sub-set of participants to gain an in depth understanding of the participant cladribine treatment and study experience.
Conditions
- Generalized Myasthenia Gravis
Interventions
PlaceboOther
Participants will receive placebo matched to cladribine in two courses separated by 4 weeks.
Cladribine Low DoseDrug
Participants will receive cladribine low dose in two courses separated by 4 weeks.
Cladribine High DoseDrug
Participants will receive cladribine high dose in two courses separated by 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Myasthenia Gravis - Activities of Daily Living (MG-ADL) Scale Score at Week 24 During the Double-Blind Placebo Controlled (DBPC) PeriodTime frame: Baseline, Week 24
Locations
159 sites in 26 countries. Site status is shown where the registry gives one.
Arizona Neuroscience Research, LLC
Phoenix, Arizona · Recruiting
Advanced Neurosciences Research LLC
Longmont, Colorado · Active not recruiting
University of Connecticut Health Center - Department of Medicine
Farmington, Connecticut · Recruiting
The George Washington University Medical Faculty Associates Foggy Bottom South Pavilion
Washington D.C., District of Columbia · Recruiting
Neurology of Central Florida Research Center, LLC
Altamonte Springs, Florida · Recruiting
SFM Clinical Research, LLC
Boca Raton, Florida · Recruiting
University of Florida Health Science Center - 300120311
Jacksonville, Florida · Recruiting
Neurology Associates, P. A.
Maitland, Florida · Recruiting
University of South Florida - PARENT - PARENT
Tampa, Florida · Recruiting
University of Kansas Medical Center Research Institute, Inc. - 3901 Rainbow (MAIN)
Kansas City, Kansas · Recruiting
UNC Hospitals - PARENT
Chapel Hill, North Carolina · Recruiting
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina · Recruiting
Miami Valley Hospital South
Centerville, Ohio · Recruiting
University of Cincinnati
Cincinnati, Ohio · Recruiting
Clinical Trials of South Carolina - Charleston
Charleston, South Carolina · Recruiting
Erlanger Health, Inc. - 1123255
Chattanooga, Tennessee · Recruiting
Baylor Scott & White Research Institute - Baylor Scott & White Research Institute
Dallas, Texas · Recruiting
ANESC Research
El Paso, Texas · Recruiting
DHR Health Institute for Research and Development
McAllen, Texas · Recruiting
Baylor Scott & White Neurology - McKinney
McKinney, Texas · Recruiting
The University of Vermont Medical Center
Burlington, Vermont · Recruiting
Integrated Neurology Services - Dr. Simon Fishman's Office
Falls Church, Virginia · Active not recruiting
BCN Research
Greenfield, Wisconsin · Recruiting
Expertia S.A- Mautalen Salud e Investigación
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Neurologicas Raul Carrea, FLENI - de Investigaciones Clinicas del área de Cardiología y enfermedades metabólicas asociadas
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Metabolicas (IDIM)
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
Hospital Cordoba
Córdoba, Argentina · Recruiting
Fundacion Rosarina de Neurorehabilitacion
Rosario, Argentina · Recruiting
INECO Neurociencias Oroño
Rosario, Argentina · Recruiting
CER San Juan Centro Polivalente de Asistencia e Inv. Clinica
San Juan, Argentina · Recruiting
Centro de Investigaciones Medicas Tucuman
San Miguel de Tucumán, Argentina · Recruiting
Gold Coast University Hospital - PARENT
Southport, Australia · Recruiting
Brain and Mind Research Institute
Camperdown, New South Wales, Australia · Recruiting
Sunshine Coast University Hospital
Birtinya, Queensland, Australia · Recruiting
Princess Alexandra Hospital - PARENT
South Brisbane, Queensland, Australia · Recruiting
John Hunter Hospital - PARENT
City of Burnside, South Australia, Australia · Recruiting
Box Hill Hospital - PARENT
Box Hill, Victoria, Australia · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
C. H. R. de la Citadelle - Account 1
Liège, Belgium · Recruiting
Medical Center Hera - branch Montana
Montana, Bulgaria · Recruiting
Showing 40 of 159 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.